Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Study to evaluate effectiveness of switching treatment to elacestrant in early breast cancer based on the detection of molecular relapse with Signatera™ Approximately 1,900 early-stage breast...
Source: marketscreener.com